Parkinson's disease (PD): investigational treatments

Evidence-based neurology checklist on parkinson's disease (pd): investigational treatments: Drug treatments ABBV-951: this delivers Levodopa subcutaneously Ambroxol: this is for GBA-PD Anle 138b: this prevents alpha-synuclein aggregation Azathioprine: this is anti-inflammatory BIA 28-6156: this is…

Drug treatments

  • ABBV-951: this delivers Levodopa subcutaneously
  • Ambroxol: this is for GBA-PD
  • Anle 138b: this prevents alpha-synuclein aggregation
  • Azathioprine: this is anti-inflammatory
  • BIA 28-6156: this is for GBA-PD
  • Buntanetap: this reduces alpha-synuclein production
  • Camacinal: this is a gastric prokinetic drug
  • Cannabinoids: these may benefit akinesia, tremor and dyskinesia
  • Ceftriaxone
  • Exenatide
  • Foslevodopa-foscarbidopa
  • Helicobacter pylori eradication: this may improve the effect of Levodopa
  • Isradipine
  • Istradefylline: this is an adenosine A2A receptor antagonist
  • Istradefylline
  • Levetiracetam
  • Lithium
  • Lixisenatide
  • Macuna pruriens
  • Memantine: this prevents alpha-synuclein transmission.
  • ND0612: this delivers Levodopa subcutaneously
  • NE-3107: this is anti-inflammatory
  • NEU-723: this is for LRRK2 PD
  • Nilotinib
  • Omarigliptin: this is an intranasal dipeptidyl peptidase 4 inhibitor
  • Origanum majorana
  • Prasinezumab
  • Rivastigmine: this is for gait impairment
  • Sargramostim: this is anti-inflammatory 
  • Selnoflast: this is anti-inflammatory
  • Sublingual apomorphine: this is for acute relief of ‘off’ episodes
  • Sulforaphane
  • Suvecaltamide: this is a T-type calcium channel inhibitor
  • Tavapadon: this is a D1/D5 receptor partial agonist
  • UCB0022: this is a positive D1 receptor modulator
  • Ulotorant: this is for PD psychosis
  • Vaccination
  • Zonisamide

Interventional treatments

Failed treatments

References

  1. McFarthing K, Buff S, Rafaloff G, et al. Parkinson's disease drug therapies in the clinical trial pipeline: 2023 update. J Parkinsons Dis 2023; 13:427-439.
  2. Greenland JC, Cutting E, Kadyan S, Bond S, Chhabra A, Williams-Gray CH. Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open. 2020; 10:e040527.
  3. Marrinan SL, Otiker T, Vasist LS, et al. A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease. Mov Disord 2018; 33:329-332.
  4. Buhmann C, Mainka T, Ebersbach G, Gandor F. Evidence for the use of cannabinoids in Parkinson's disease. J Neural Transm (Vienna) 2019; doi: 10.1007/s00702-019-02018-8 (Epub ahead of print).
  5. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390:1664-1675.
  6. And 45 more. Subscribe to see the full list

Related checklists

Loading...